THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 30, 2008--Amgen (NASDAQ: AMGN) issued the following statement in response to the receipt today of the complete response on the revised ESA labeling from the FDA.
"This label is consistent with our expectations. We will soon be communicating the revised product labeling for ESAs to both physicians and patients."
The potential impact of this revised label was factored into our updated guidance announced July 28, 2008.
CONTACT: Amgen, Thousand Oaks
Trish Hawkins, 805-447-5631 (media)
Arvind Sood, 805-447-1060 (investors)